Please login to the form below

Not currently logged in
Email:
Password:

immuno-oncology

This page shows the latest immuno-oncology news and features for those working in and with pharma, biotech and healthcare.

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy

collaborations and licensing deals with academic and industrial partners, which now number 55 across “immuno-oncology, gene editing and regenerative medicine.”.

Latest news

More from news
Approximately 60 fully matching, plus 223 partially matching documents found.

Latest Intelligence

  • Cancer in The Information Age: are we illuminated or inundated? Cancer in The Information Age: are we illuminated or inundated?

    Effective treatments for these diseases are currently being explored in more than 20, 000 open and active studies registered on ClinicalTrials.gov, 2, 000 of which are immuno-oncology-specific trials. ... Fed by this information and data, the oncology

  • Let’s change the conversation about cancer Let’s change the conversation about cancer

    The group discussed the impact of recent developments in cancer therapies, such as immuno-oncology (IO). ... Watch the full Switched Oncology Patient Experience focus group here or visit Switched Oncology for more information.

  • Deal Watch January 2018

    Licence. 339. TeneoBio/TESARO. Multi-specific antibodies for up to six undisclosed oncology targets using UniRat® platform and discovery engine TeneoSeek. ... used to progress the clinical development of the company's immuno-oncology antibody

  • The good, the bad and the ugly The good, the bad and the ugly

    Oncology. Oncology has long been a key area of profit opportunity, but the recent explosion of immuno-oncology treatments has further extended the possibilities for growth. ... The oncology market is certainly evolving. “Some of the most interesting

  • Accelerating innovation Accelerating innovation

    Leading this work is an agreement with Bristol-Myers Squibb to study a combination of Cabometyx and that firm’s blockbuster immuno-oncology drug Opdivo (nivolumab) and an agreement with Roche ... We are open to. more collaborations… potentially

More from intelligence
Approximately 1 fully matching, plus 44 partially matching documents found.

Latest appointments

  • Redx Pharma appoints new chief medical officer Redx Pharma appoints new chief medical officer

    Dr Saunders has worked in the oncology field for over 25 years and has experience in all aspects of the clinical development of oncology drugs. ... He joins the UK biotech from Lytix Biopharma, a Norweigan immuno-oncology biotech, where he also served as

  • Targovax appoints Michael Bogenstaetter as chief business officer Targovax appoints Michael Bogenstaetter as chief business officer

    Targovax appoints Michael Bogenstaetter as chief business officer. He joins the immuno-oncology biotech from Interim Assignments.

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    Lilly bolsters its oncology team. Kimberly Blackwell is appointed VP early phase development, immuno-oncology. ... Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    BMS’ Dr Mike Burgees joins Turnstone Biologics. He joins the immuno-oncology group as its president of R&D. ... Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral immunotherapies and powerful

  • Turnstone Biologics bolsters leadership team Turnstone Biologics bolsters leadership team

    Canadian immuno-oncology company Turnstone Biologics has strengthened its leadership team with the addition of two new hires.

More from appointments
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest from PMHub

  • SWITCHED ONcology

    We are stronger together. We are Switched ON. Switched ONcology is the latest thought leadership campaign from the award-winning Havas lynx portfolio. ... The campaign provides our partners with deeper insight, smarter ideas and more meaningful

  • The Big Communication - matching unprecedented clinical advances in immunotherapy with transformative communication

    In this white paper, we explore the exciting new frontier of cancer treatment - immuno-oncology (IO) - and what it means for how we communicate with healthcare professionals, patients and carers.

  • Medical information in precision medicine

    We are not treating the partnership as just another oncology medicine – it’ s a molecular information service, and that requires a great level of scientific understanding.

  • Video: Immuno-oncology therapies

    Video: Immuno-oncology therapies. Immuno-oncology therapies which harness the body’ s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. ... In this video Director Sue Marett discusses the opportunities

  • Video: Immuno-oncology therapies

    Video: Immuno-oncology therapies. Immuno-oncology therapies which harness the body’ s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. ... In this video Director Sue Marett discusses the opportunities

More from PMHub
Approximately 20 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics